HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.

Abstract
Great strides have been made in triple negative breast cancer (TNBC) treatment, which represents 20% of total predicted annual US breast cancer (BC) cases. Despite the development of several therapeutics, TNBC patients have poor overall survival rate, compared to other BC patients, justifying the urgent need to discover new entities for use to control TNBC. Chalcones are important natural products with diverse bioactivities including anticancer effects. This study aimed to design, synthesize and validate novel chalcone leads as potential therapies for TNBC. Fourteen novel chalcone analogs were designed and synthesized comprising alicyclic amines (pyrrolidine, morpholine and piperidine) or nitrogen mustard (Bis-(2-chloroethyl) amine) substituents. Among them, compound 14((E)-3-(4-(Bis(2-chloroethyl) amino) phenyl)-1-(3-methoxyphenyl) prop-2-en-1-one) was identified as the most effective against TNBC and other BC phenotypes, with anti-proliferative IC50 values ranging between 3.94 and 9.22 μM against the TNBC cell lines MDA-MB-231 and MDA-MB-468, as well as against the estrogen positive MCF-7 cell line. Chalcone 14 effectively suppressed the colony formation capacity of MDA-MB-231, MDA-MB-468, and MCF-7 cell lines at 5 and 10 μM treatment concentrations. Furthermore, compound 14 has significantly inhibited cell invasion and migration of MDA-MB-231 and MCF-7 BC cell lines. Additionally, compound 14 had significantly promoted apoptosis by upregulating BAX and downregulating Bcl-2 proteins. Compound 14 induced significant cell cycle arrest of TNBC cells at the G2/M phase. It also induced a reversal of Epithelial Mesenchymal Transition (EMT) by upregulating the epithelial markers E-cadherin and Pan-cadherin and downregulating FAK. Furthermore, it had dramatically diminished new vessel formation (vasculogenesis) in chick chorioallantoic membrane (CAM) model by 60.20 ± 8.47%. Chalcone 14 inhibited 46.41 ± 0.71% of the TNBC MAD-MB-231 cells growth in a nude mouse orthotopic xenograft model in comparison with vehicle control treated animals. Collectively, this study results propose chalcone 14 as a promising lead molecule for the control of TNBC as well as other breast cancer phenotypes.
AuthorsDana Elkhalifa, Abu Bakar Siddique, Mohammed Qusa, Farhan S Cyprian, Khalid El Sayed, Feras Alali, Ala-Eddin Al Moustafa, Ashraf Khalil
JournalEuropean journal of medicinal chemistry (Eur J Med Chem) Vol. 187 Pg. 111954 (Feb 01 2020) ISSN: 1768-3254 [Electronic] France
PMID31838326 (Publication Type: Journal Article)
CopyrightCopyright © 2019 Elsevier Masson SAS. All rights reserved.
Chemical References
  • Chalcone
  • Nitrogen
Topics
  • Animals
  • Apoptosis (drug effects)
  • Cell Cycle Checkpoints (drug effects)
  • Cell Proliferation (drug effects)
  • Cell Survival (drug effects)
  • Chalcone (chemical synthesis, chemistry, pharmacology)
  • Dose-Response Relationship, Drug
  • Drug Design
  • Drug Screening Assays, Antitumor
  • Female
  • Humans
  • Mammary Neoplasms, Experimental (drug therapy, pathology)
  • Mice
  • Mice, Nude
  • Models, Molecular
  • Molecular Structure
  • Nitrogen (chemistry, pharmacology)
  • Structure-Activity Relationship
  • Triple Negative Breast Neoplasms (drug therapy, pathology)
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: